Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Neonatal T Follicular Helper Cells Are Lodged in a Pre-T Follicular Helper Stage Favoring Innate Over Adaptive Germinal Center Responses.

Mastelic-Gavillet B, Vono M, Gonzalez-Dias P, Ferreira FM, Cardozo L, Lambert PH, Nakaya HI, Siegrist CA.

Front Immunol. 2019 Aug 13;10:1845. doi: 10.3389/fimmu.2019.01845. eCollection 2019.

2.

Maternal Antibodies Inhibit Neonatal and Infant Responses to Vaccination by Shaping the Early-Life B Cell Repertoire within Germinal Centers.

Vono M, Eberhardt CS, Auderset F, Mastelic-Gavillet B, Lemeille S, Christensen D, Andersen P, Lambert PH, Siegrist CA.

Cell Rep. 2019 Aug 13;28(7):1773-1784.e5. doi: 10.1016/j.celrep.2019.07.047.

3.

Site-Specific DC Surface Signatures Influence CD4+ T Cell Co-stimulation and Lung-Homing.

Pejoski D, Ballester M, Auderset F, Vono M, Christensen D, Andersen P, Lambert PH, Siegrist CA.

Front Immunol. 2019 Jul 18;10:1650. doi: 10.3389/fimmu.2019.01650. eCollection 2019.

4.

Long-term seroprotection of varicella-zoster immunization in pediatric liver transplant recipients.

Verolet CM, Pittet LF, Wildhaber BE, McLin VA, Rodriguez M, Grillet S, Siegrist CA, Posfay-Barbe KM.

Transplantation. 2019 Jul 15. doi: 10.1097/TP.0000000000002866. [Epub ahead of print]

PMID:
31335765
5.

Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation.

Auderset F, Ballester M, Mastelic-Gavillet B, Fontannaz P, Chabaud-Riou M, Reveneau N, Garinot M, Mistretta N, Liu Y, Lambert PH, Ochs M, Siegrist CA.

Front Immunol. 2019 Jul 3;10:1520. doi: 10.3389/fimmu.2019.01520. eCollection 2019.

6.

High Immunogenicity of the Pneumococcal Conjugated Vaccine in Immunocompromised Adults With Inflammatory Bowel Disease.

Pittet LF, Verolet CM, Michetti P, Girardin M, Juillerat P, Mottet C, Maillard MH, Siegrist CA, Posfay-Barbe KM; Swiss Inflammatory Bowel Disease Cohort Study Group.

Am J Gastroenterol. 2019 Jul;114(7):1130-1141. doi: 10.14309/ajg.0000000000000289.

PMID:
31205131
7.

Safety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study.

Bühler S, Jaeger VK, Adler S, Bannert B, Brümmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, Müller R, Nissen MJ, Siegrist CA, Villiger PM, Walker UA, Hatz C.

Rheumatology (Oxford). 2019 Sep 1;58(9):1585-1596. doi: 10.1093/rheumatology/kez045.

PMID:
30877773
8.

Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.

Blanchard Rohner G, Chatzis O, Chinwangso P, Rohr M, Grillet S, Salomon C, Lemaître B, Boonrak P, Lawpoolsri S, Clutterbuck E, Poredi IK, Wijagkanalan W, Spiegel J, Pham HT, Viviani S, Siegrist CA.

Clin Infect Dis. 2019 Mar 19;68(7):1213-1222. doi: 10.1093/cid/ciy594.

PMID:
30759183
9.

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Huttner A, Siegrist CA.

Expert Rev Vaccines. 2018 Dec;17(12):1105-1110. doi: 10.1080/14760584.2018.1546582. Epub 2018 Nov 15. Review.

PMID:
30422031
10.

Putting patients at the center of kidney care transitions: PREPARE NOW, a cluster randomized controlled trial.

Green JA, Ephraim PL, Hill-Briggs FF, Browne T, Strigo TS, Hauer CL, Stametz RA, Darer JD, Patel UD, Lang-Lindsey K, Bankes BL, Bolden SA, Danielson P, Ruff S, Schmidt L, Swoboda A, Woods P, Vinson B, Littlewood D, Jackson G, Pendergast JF, St Clair Russell J, Collins K, Norfolk E, Bucaloiu ID, Kethireddy S, Collins C, Davis D, dePrisco J, Malloy D, Diamantidis CJ, Fulmer S, Martin J, Schatell D, Tangri N, Sees A, Siegrist C, Breed J Jr, Medley A, Graboski E, Billet J, Hackenberg M, Singer D, Stewart S, Alkon A, Bhavsar NA, Lewis-Boyer L, Martz C, Yule C, Greer RC, Saunders M, Cameron B, Boulware LE.

Contemp Clin Trials. 2018 Oct;73:98-110. doi: 10.1016/j.cct.2018.09.004. Epub 2018 Sep 12.

11.

Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation.

Pittet LF, Verolet CM, McLin VA, Wildhaber BE, Rodriguez M, Cherpillod P, Kaiser L, Siegrist CA, Posfay-Barbe KM.

Am J Transplant. 2019 Mar;19(3):844-854. doi: 10.1111/ajt.15101. Epub 2018 Oct 1.

PMID:
30171797
12.

Usefulness of a systematic approach at listing for vaccine prevention in solid organ transplant candidates.

Blanchard-Rohner G, Enriquez N, Lemaître B, Cadau G, Combescure C, Giostra E, Hadaya K, Meyer P, Gasche-Soccal PM, Berney T, van Delden C, Siegrist CA.

Am J Transplant. 2019 Feb;19(2):512-521. doi: 10.1111/ajt.15097. Epub 2018 Oct 12.

PMID:
30144276
13.

Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland's largest pre-trial prison.

Gétaz L, Casillas A, Siegrist CA, Chappuis F, Togni G, Tran NT, Baggio S, Negro F, Gaspoz JM, Wolff H.

J Glob Health. 2018 Dec;8(2):020407. doi: 10.7189/jogh-08-020407.

14.

Toll-Interleukin 1 Receptor Domain-Containing Adaptor Protein 180L Single-Nucleotide Polymorphism Is Associated With Susceptibility to Recurrent Pneumococcal Lower Respiratory Tract Infections in Children.

Siebert JN, Hamann L, Verolet CM, Gameiro C, Grillet S, Siegrist CA, Posfay-Barbe KM.

Front Immunol. 2018 Aug 7;9:1780. doi: 10.3389/fimmu.2018.01780. eCollection 2018.

15.

Correlates of vaccine-induced protective immunity against Ebola virus disease.

Medaglini D, Santoro F, Siegrist CA.

Semin Immunol. 2018 Oct;39:65-72. doi: 10.1016/j.smim.2018.07.003. Epub 2018 Jul 21. Review.

16.

Immune system correlates of extensive limb swelling in response to conjugated pneumococcal vaccination.

Recher M, Hirsiger JR, Bigler MB, Iff M, Lemaître B, Scherer K, Häusermann P, Siegrist CA, Berger CT.

NPJ Vaccines. 2018 May 18;3:17. doi: 10.1038/s41541-018-0059-3. eCollection 2018.

17.

[Prevention of influenza in acute care settings : a multimodal intervention].

Iten A, Bonfillon C, Siegrist CA, Kaiser L, Pittet D.

Rev Med Suisse. 2018 Apr 11;14(602):800-805. French.

PMID:
29658221
18.

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

Huttner A, Agnandji ST, Combescure C, Fernandes JF, Bache EB, Kabwende L, Ndungu FM, Brosnahan J, Monath TP, Lemaître B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist CA; VEBCON; VSV-EBOVAC; VSV-EBOPLUS Consortia.

Lancet Infect Dis. 2018 Jul;18(7):738-748. doi: 10.1016/S1473-3099(18)30165-8. Epub 2018 Apr 5.

19.

Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan.

Vono M, Eberhardt CS, Mohr E, Auderset F, Christensen D, Schmolke M, Coler R, Meinke A, Andersen P, Lambert PH, Mastelic-Gavillet B, Siegrist CA.

Front Immunol. 2018 Feb 28;9:381. doi: 10.3389/fimmu.2018.00381. eCollection 2018.

20.

AS03- and MF59-Adjuvanted Influenza Vaccines in Children.

Wilkins AL, Kazmin D, Napolitani G, Clutterbuck EA, Pulendran B, Siegrist CA, Pollard AJ.

Front Immunol. 2017 Dec 13;8:1760. doi: 10.3389/fimmu.2017.01760. eCollection 2017. Review.

21.

Antenatal vaccination to decrease pertussis in infants: safety, effectiveness, timing, and implementation.

Lumbreras Areta M, Eberhardt CS, Siegrist CA, Martinez de Tejada B.

J Matern Fetal Neonatal Med. 2019 May;32(9):1541-1546. doi: 10.1080/14767058.2017.1406475. Epub 2017 Dec 3. Review.

PMID:
29199493
22.

Cautious Interpretation of Optimal Timing of Maternal Pertussis Immunization.

Eberhardt CS, Combescure C, Siegrist CA.

Clin Infect Dis. 2017 Oct 30;65(10):1766. doi: 10.1093/cid/cix536. No abstract available.

PMID:
28595351
23.

Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.

Medaglini D, Siegrist CA.

Curr Opin Virol. 2017 Apr;23:88-94. doi: 10.1016/j.coviro.2017.03.008. Epub 2017 Apr 28. Review.

24.

A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

Huttner A, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Agnandji ST, Brosnahan J, Dayer JA, Harandi AM, Kaiser L, Medaglini D, Monath T; VEBCON and VSV-EBOVAC Consortia, Roux-Lombard P, Kremsner PG, Ottenhoff TH, Siegrist CA.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaaj1701. doi: 10.1126/scitranslmed.aaj1701. Erratum in: Sci Transl Med. 2019 Aug 21;11(506):.

25.

Pertussis Antibody Transfer to Preterm Neonates After Second- Versus Third-Trimester Maternal Immunization.

Eberhardt CS, Blanchard-Rohner G, Lemaître B, Combescure C, Othenin-Girard V, Chilin A, Petre J, Martinez de Tejada B, Siegrist CA.

Clin Infect Dis. 2017 Apr 15;64(8):1129-1132. doi: 10.1093/cid/cix046.

26.

What Is Wrong with Pertussis Vaccine Immunity? Inducing and Recalling Vaccine-Specific Immunity.

Eberhardt CS, Siegrist CA.

Cold Spring Harb Perspect Biol. 2017 Dec 1;9(12). pii: a029629. doi: 10.1101/cshperspect.a029629. Review.

PMID:
28289058
27.

Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey.

Dayer JA, Siegrist CA, Huttner A.

PLoS One. 2017 Mar 8;12(3):e0173148. doi: 10.1371/journal.pone.0173148. eCollection 2017.

28.

Attitudes of Swiss Health Care Providers Toward Childhood Immunizations.

Schuler M, Schaedelin S, Aebi C, Berger C, Crisinel PA, Diana A, Niederer-Loher A, Siegrist CA, Vaudaux B, Heininger U.

Pediatr Infect Dis J. 2017 Jun;36(6):e167-e174. doi: 10.1097/INF.0000000000001522.

PMID:
28030524
29.

Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.

Sirivichayakul C, Chanthavanich P, Limkittikul K, Siegrist CA, Wijagkanalan W, Chinwangso P, Petre J, Hong Thai P, Chauhan M, Viviani S.

Hum Vaccin Immunother. 2017 Jan 2;13(1):136-143. doi: 10.1080/21645515.2016.1234555. Epub 2016 Sep 29.

30.

Optimizing seroprotection against pneumococcus in children with nephrotic syndrome using the 13-valent pneumococcal conjugate vaccine.

Pittet LF, Posfay-Barbe KM, Chehade H, Rudin C, Wilhelm-Bals A, Rodriguez M, Siegrist CA, Parvex P.

Vaccine. 2016 Sep 22;34(41):4948-4954. doi: 10.1016/j.vaccine.2016.08.049. Epub 2016 Aug 26.

PMID:
27576076
31.

IL-36-Induced Toxicity in Neonatal Mice Involves TNF-α Production by Liver Myeloid Cells.

Palomo J, Mastelic-Gavillet B, Woldt E, Troccaz S, Rodriguez E, Palmer G, Siegrist CA, Gabay C.

J Immunol. 2016 Sep 15;197(6):2239-49. doi: 10.4049/jimmunol.1600700. Epub 2016 Aug 15.

32.

Method for measuring the unbinding energy of strongly-bound membrane-associated proteins.

Bauve E, Vernon BC, Ye D, Rogers DM, Siegrist CM, Carson BD, Rempe SB, Zheng A, Kielian M, Shreve AP, Kent MS.

Biochim Biophys Acta. 2016 Nov;1858(11):2753-2762. doi: 10.1016/j.bbamem.2016.07.004. Epub 2016 Jul 15.

33.

Vaccination in early life: standing up to the challenges.

Mohr E, Siegrist CA.

Curr Opin Immunol. 2016 Aug;41:1-8. doi: 10.1016/j.coi.2016.04.004. Epub 2016 Apr 19. Review.

PMID:
27104290
34.

Reply to Abu Raya et al.

Eberhardt CS, Martinez de Tejada B, Siegrist CA.

Clin Infect Dis. 2016 Jul 1;63(1):144-5. doi: 10.1093/cid/ciw235. Epub 2016 Apr 18. No abstract available.

PMID:
27090994
35.

Btn2a2, a T cell immunomodulatory molecule coregulated with MHC class II genes.

Sarter K, Leimgruber E, Gobet F, Agrawal V, Dunand-Sauthier I, Barras E, Mastelic-Gavillet B, Kamath A, Fontannaz P, Guéry L, Duraes Fdo V, Lippens C, Ravn U, Santiago-Raber ML, Magistrelli G, Fischer N, Siegrist CA, Hugues S, Reith W.

J Exp Med. 2016 Feb 8;213(2):177-87. doi: 10.1084/jem.20150435. Epub 2016 Jan 25.

36.

Maternal Immunization Earlier in Pregnancy Maximizes Antibody Transfer and Expected Infant Seropositivity Against Pertussis.

Eberhardt CS, Blanchard-Rohner G, Lemaître B, Boukrid M, Combescure C, Othenin-Girard V, Chilin A, Petre J, de Tejada BM, Siegrist CA.

Clin Infect Dis. 2016 Apr 1;62(7):829-836. doi: 10.1093/cid/ciw027. Epub 2016 Jan 20.

37.

Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood.

Nakaya HI, Clutterbuck E, Kazmin D, Wang L, Cortese M, Bosinger SE, Patel NB, Zak DE, Aderem A, Dong T, Del Giudice G, Rappuoli R, Cerundolo V, Pollard AJ, Pulendran B, Siegrist CA.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1853-8. doi: 10.1073/pnas.1519690113. Epub 2016 Jan 11.

38.

Ebola vaccine R&D: Filling the knowledge gaps.

Medaglini D, Harandi AM, Ottenhoff TH, Siegrist CA; VSV-Ebovac Consortium.

Sci Transl Med. 2015 Dec 9;7(317):317ps24. doi: 10.1126/scitranslmed.aad3106. Review.

PMID:
26659569
39.

Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.

Sommerstein R, Flatz L, Remy MM, Malinge P, Magistrelli G, Fischer N, Sahin M, Bergthaler A, Igonet S, Ter Meulen J, Rigo D, Meda P, Rabah N, Coutard B, Bowden TA, Lambert PH, Siegrist CA, Pinschewer DD.

PLoS Pathog. 2015 Nov 20;11(11):e1005276. doi: 10.1371/journal.ppat.1005276. eCollection 2015 Nov.

40.

The Nucleoprotein Is Required for Lymphocytic Choriomeningitis Virus-Based Vaccine Vector Immunogenicity.

Darbre S, Johnson S, Kallert S, Lambert PH, Siegrist CA, Pinschewer DD.

J Virol. 2015 Nov;89(22):11734-8. doi: 10.1128/JVI.01613-15. Epub 2015 Sep 9.

41.

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium.

Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4.

42.

Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases.

Bühler S, Eperon G, Ribi C, Kyburz D, van Gompel F, Visser LG, Siegrist CA, Hatz C.

Swiss Med Wkly. 2015 Jul 28;145:w14159. doi: 10.4414/smw.2015.14159. eCollection 2015.

43.

Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report.

Schibler M, Vetter P, Cherpillod P, Petty TJ, Cordey S, Vieille G, Yerly S, Siegrist CA, Samii K, Dayer JA, Docquier M, Zdobnov EM, Simpson AJH, Rees PSC, Sarria FB, Gasche Y, Chappuis F, Iten A, Pittet D, Pugin J, Kaiser L.

Lancet Infect Dis. 2015 Sep;15(9):1034-1040. doi: 10.1016/S1473-3099(15)00229-7. Epub 2015 Jul 19.

PMID:
26201298
44.

Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study.

Hatz CF, Bally B, Rohrer S, Steffen R, Kramme S, Siegrist CA, Wacker M, Alaimo C, Fonck VG.

Vaccine. 2015 Aug 26;33(36):4594-601. doi: 10.1016/j.vaccine.2015.06.102. Epub 2015 Jul 7.

PMID:
26162850
45.

Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: Preclinical proof of concept.

Gavillet BM, Mondoulet L, Dhelft V, Eberhardt CS, Auderset F, Pham HT, Petre J, Lambert PH, Benhamou PH, Siegrist CA.

Vaccine. 2015 Jul 9;33(30):3450-5. doi: 10.1016/j.vaccine.2015.05.089. Epub 2015 Jun 9.

46.

Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study.

Fischer L, Gerstel PF, Poncet A, Siegrist CA, Laffitte E, Gabay C, Seebach JD, Ribi C.

Arthritis Res Ther. 2015 Jun 6;17:151. doi: 10.1186/s13075-015-0663-9.

47.

MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life.

Mastelic Gavillet B, Eberhardt CS, Auderset F, Castellino F, Seubert A, Tregoning JS, Lambert PH, de Gregorio E, Del Giudice G, Siegrist CA.

J Immunol. 2015 May 15;194(10):4836-45. doi: 10.4049/jimmunol.1402071. Epub 2015 Apr 13.

48.

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA.

N Engl J Med. 2016 Apr 28;374(17):1647-60. doi: 10.1056/NEJMoa1502924. Epub 2015 Apr 1.

49.

Protective efficacy of individual CD8+ T cell specificities in chronic viral infection.

Johnson S, Bergthaler A, Graw F, Flatz L, Bonilla WV, Siegrist CA, Lambert PH, Regoes RR, Pinschewer DD.

J Immunol. 2015 Feb 15;194(4):1755-62. doi: 10.4049/jimmunol.1401771. Epub 2015 Jan 7.

50.

Bordetella holmesii: an under-recognised Bordetella species.

Pittet LF, Emonet S, Schrenzel J, Siegrist CA, Posfay-Barbe KM.

Lancet Infect Dis. 2014 Jun;14(6):510-9. doi: 10.1016/S1473-3099(14)70021-0. Epub 2014 Apr 7. Review.

PMID:
24721229

Supplemental Content

Loading ...
Support Center